Onco Actu du 20 décembre 2017

	2.6 Etiologie - Environnement
EPA says herbicide in Roundup weed killer doesn't cause cancer, contradicting California regulators [LA Times] The assessment contradicts the conclusion of a European scientific panel as well as California regulators, who have included the chemical on the Proposition 65 list of probable carcinogens.
	3. Prévention
Personalised prevention in breast cancer – the policy landscape [PHG] Personalised healthcare and personalised prevention are gaining prominence in policy debates. Yet our research suggests there is little in the way of a coherent and consistent policy approach specifically focused on the personalised prevention of breast cancer.
	3.1 Prévention - Tabac
Smoking ban cannot be enforced in jails, UK supreme court rules [The Guardian] A prisoner suffering from poor health has lost his attempt to enforce the smoking ban in English and Welsh jails after the supreme court ruled that crown premises are effectively exempt from the enforcement of health regulations.
	4. Dépistage, diagnostic et pronostic
Cutting cancer diagnosis delays means understanding each patient’s journey [Cancer Research UK] “The data gathered in this audit is really rich and we have only just scratched the surface,” says Swann. “Each general practice has received its own individual results so the practice team can identify areas where they could improve.” And many are already making changes.
Too Many Older Patients Get Cancer Screenings [NY Times] “It’s jarring for someone who’s been told every year to get screened and then at age 75 you tell them to stop,” she said. John Randall, 78, says he plans to live into his 90s. He sees no reason to skip cancer screening.
	4.12 Biopsies liquides
Oncologists, Beware: Expensive Liquid Biopsy Tests Produce Conflicting Results [Forbes] The stakes are extremely high for oncologists putting their trust in liquid biopsy tests, and this important study suggests that the technology is simply not ready to help them make critical decisions for patients.
	4.9 Dép., diag. & prono. - Sein
MRI could detect signs of more aggressive breast cancers [Institute of Cancer Research] Writing in the journal European Radiology, the team from The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust explained how they performed their research, which was done in rats with chemically-induced breast tumours that show a range of fibrosis levels.
	5. Traitements
Combination Rethink [Harvard Medical School] This finding differs from current hypotheses about drug interaction, which have commonly explained benefits as arising from drug synergy. However, this should not be interpreted as diminishing the value of combination therapy for patients, the team cautions.
NIH study uncovers clues about why common cancer drug causes hearing loss [NIH] Using a highly sensitive technique to measure and map cisplatin in mouse and human inner ear tissues, researchers found that forms of cisplatin build up in the inner ear. They also found a region in the inner ear that could be targeted for efforts to prevent hearing loss from cisplatin.
	5.10 Traitements - Essais
Creating electric fields in the brain buys glioblastoma patients extra months of life [STAT] In the real world, the benefits of a treatment are often less than what they were in a clinical trial, and that might be the case here, too. This company-sponsored study enrolled only patients who were well enough to start chemo after surgery and radiation, said Stupp: “We could not include the absolutely worst patients.”
Electronic cap treatment improves brain tumour survival [Cancer Research UK] The device delivers low-intensity electricity to the brain through 9 insulated electrodes, placed on the patient’s shaved scalp using a cap. These doses of electricity, called Tumour Treating Fields (TTFields), interfere with the molecular machinery inside cancer cells that helps them divide.
	5.12.1 Immunothérapies - partenariats
Stepping up behind Sanofi, Genentech rolls the DiCE on a new small molecule discovery pact [EndPoints] DiCE will now divvy up its work between its two large-scale collaborations as well as the in-house work it’s doing on its own. In-house the biotech is furthest along with an immunology program, with more work focused on immuno-oncology.
	5.2 Pharma
AstraZeneca snags Tagrisso 'breakthrough' in first-line EGFR lung cancer patients [FiercePharma] A first-line nod would mean big things for Tagrisso, whose patient pool is currently limited to those with an abnormal T790M gene who have failed on other treatments.
Is Roche’s pRED finally ready to step out from behind Genentech for its closeup? Probably not [EndPoints] It’s unusual for any giant pharma company like Roche to tout mid-stage programs, which have a high mortality rate, especially as marketing challenges can now just as easily kill off a program just as surely as bad data ever could.
Novocure Receives FDA IDE Approval for its PANOVA 3 Phase 3 Pivotal Clinical Trial in Advanced Pancreatic Cancer [Novocure] Tumor Treating Fields in combination with nab-paclitaxel and gemcitabine more than doubled progression free survival and the one-year survival rate compared to historical controls in Novocure’s phase 2 pilot trial in advanced pancreatic cancer.
	5.2.1 Pharma - Partenariats
Array Biopharma ties up with Pfizer on cancer-fighting combos [FierceBiotech] The study is slated to kick off by the third quarter of 2018, Array said. A multi-arm trial to determine the best dosing is expected to follow.
Array BioPharma Announces Strategic Collaboration with Pfizer [Array] Novel combinations of binimetinib (MEK), avelumab (PD-L1), and talazoparib (PARP inhibitor) to be studied across tumor types.
Array joins Pfizer on anti-cancer combos, the latest in a string of binimetinib combinations [EndPoints] The companies will start with combining Array’s MEK inhibitor binimetinib with Pfizer’s investigational PARP inhibitor talazoparib, and avelumab, a human anti-PD-L1 IgG1 monoclonal antibody.
	5.2.3 Pharma - économie
Enticed by tax reform, Pfizer ups dividend, marks $10B for buybacks. Who's next? [FiercePharma] President Donald Trump has long trumpeted the idea that slashing the corporate tax rate would spur job growth. But if Pfizer is any indication, hiring is likely fairly low down on the priority list for Big Pharma.
Pfizer Shareholders Are Already Enjoying the Fruits of Tax Cuts [Bloomberg] It's the first sign of something that shouldn't be especially surprising -- Corporate America's tax-bill gains are largely going straight back to shareholders, rather than toward investment or (heaven forfend) wage increases.
Drug Industry Spent Millions To Squelch Talk About High Drug Prices [KHN] The $57 million PhRMA spent on lobbying was also the most since 2009, when the lobbying bill was $70 million. So was the $7 million spent on advertising, a cost that should rise this year, since the “Go Boldly” ads aired in 2017. PhRMA employed 237 people last year, up from fewer than 200 in 2011.
	5.3.4 Traitements - AMM (FDA, EMA)
Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) Tablets for Previously Untreated Advanced Renal Cell Carcinoma [Exelixis] The FDA’s priority review and approval of CABOMETYX was based on results from the randomized phase 2 CABOSUN trial in patients with previously untreated RCC, which demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus sunitinib, a current standard of care.
U.S. FDA Approves Pfizer’s BOSULIF® (bosutinib) for the Treatment of Patients with Newly-Diagnosed Ph+ Chronic Myelogenous Leukemia (CML) [Pfizer] Pfizer’s Third U.S. Hematology Approval in Five Months.
Pfizer, Exelixis cancer drugs get FDA approval for wider use [Reuters] Pfizer’s Bosulif was expanded to treat newly-diagnosed adult patients with a rare, chronic form of blood cancer. The U.S. regulator expanded the label of Exelixis’s drug, Cabometyx, to treat patients with the most common form of kidney cancer.
	5.4 Traitements - Economie
‘Drugs are too expensive for the NHS – and people are paying with their lives’ [The Guardian] Arms aloft, activist and breast cancer patient Emma Robertson emerged from the UK headquarters of pharmaceutical giant Pfizer last month wearing a bright blue T-shirt. Emblazoned on the back in bold yellow letters were the words: “No drug should ever cost a life”.
	5.5 ASCO
Howard A. “Skip” Burris III, MD, FACP, FASCO, Elected ASCO President for 2019-2020 Term [ASCO] An active ASCO member since 1991, Dr. Burris is president of clinical operations and chief medical officer for Sarah Cannon, the Cancer Institute of HCA Healthcare.
	6. Lutte contre les cancers
Anticipating fundamental change in oncology [The Cancer Letter] For several years now, The Cancer Letter has been writing about breaking down silos. We will ring in 2018 by smashing the walls of our own silos.
	6.10.1 Politiques (USA)
Take Action Now: Urge Congress to Address Three Cancer Policy Priorities by the End of the Year [ASCO] In the final weeks of 2017, lawmakers are finalizing legislation that could impact access to cancer care and cancer research progress. To ensure oncologists remain able to provide high-quality care for individuals with cancer in 2018 and beyond, ASCO calls on Congress to take three key steps before it recesses for the year.